Capstone Holding Corp. lowers convertible note conversion price to $1.00
Miami-based Telomir Pharmaceuticals , Inc. (NASDAQ:TELO), currently valued at $75.6 million in market capitalization, has announced the successful completion of a $3 million equity financing round. The transaction involved the sale of 1 million restricted shares at $3.00 each, an 18% premium over the last closing price - notable given the stock is trading near its 52-week low of $2.25, down significantly from its high of $8.40. The funding was provided by The Bayshore Trust, linked to the company’s largest shareholder.
This equity sale, conducted on Sunday, May 19, 2025, did not include warrants, discounts, or convertible features, indicating strong confidence from the insider investor. The proceeds are earmarked for the regulatory and development activities of Telomir-1, the company’s drug candidate for a rare disease, including its upcoming Investigational New Drug (IND) submission. According to InvestingPro data, the company operates with a current ratio of 0.75, indicating its short-term obligations exceed liquid assets.
Previously, on December 9, 2024, Telomir Pharmaceuticals received a $1 million investment at $7.00 per share from The Starwood Trust, another entity associated with the major shareholder. Additionally, the company has access to an undrawn $5 million non-dilutive line of credit from the same group.
The shares were sold in a private placement and Telomir Pharmaceuticals claims exemption from registration under the Securities Act of 1933, as per Section 4(a)(2) and Regulation D, citing reasons such as the investment not involving a public offering and the recipient being an accredited investor.
This strategic move is intended to strengthen Telomir Pharmaceuticals’ balance sheet and support its continued efforts in drug development and regulatory submissions. The investment reflects a positive outlook from the company’s insiders and provides financial resources necessary for the advancement of their therapeutic pipeline.
The details of this financial transaction were disclosed in a recent SEC filing by the company. With the company’s next earnings report due on May 28, 2025, investors seeking deeper insights into Telomir’s financial health and growth prospects can access additional analysis through InvestingPro, which offers 8 more key tips about the company’s performance and outlook.
In other recent news, Telomir Pharmaceuticals has announced the development of Telomir-Ag2, a promising drug candidate aimed at treating bacterial infections resistant to current treatments. This development leverages the company’s Telomir-1 platform and has shown broad-spectrum antimicrobial activity in preclinical studies, particularly against methicillin- and aminoglycoside-resistant Staphylococcus aureus. Meanwhile, Telomir-1, another drug candidate from the company, has demonstrated potential in reversing cellular aging processes and reducing tumor growth by 50% in a prostate cancer animal model. The drug also appears to mitigate chemotherapy-induced toxicity, offering protective benefits against the adverse effects of Paclitaxel. These findings were part of preclinical studies and have not yet been tested in humans. Additionally, Telomir Pharmaceuticals plans to engage with the FDA’s Rare Disease Endpoint Advancement Pilot Program to advance the development of Telomir-1 for rare diseases. The company is also exploring partnerships in wound care, infectious disease, and medical devices, aiming to bring these drug candidates to clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.